Cridanimod
Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer[1][2].
Product Specifications
CAS Number
[38609-97-1]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
IFNAR; Progesterone Receptor
Type
Reference compound
Related Pathways
Immunology/Inflammation; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/cridanimod.html
Purity
99.97
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O
Molecular Formula
C15H11NO3
Molecular Weight
253.26
Precautions
H302, H315, H319, H335
References & Citations
[1]Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016|[2]Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
